SCHEMBL6496009

SCHEMBL6496009

CC(=O)Nc1ccc(-c2ccc(C(=O)NC3CC4CNC3C4)o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MMP13 P45452 1/20 0.48
MAPT P10636 3/20 0.43
TP53 P04637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ALDH1A1 P00352 3/20 0.43
NPSR1 Q6W5P4 3/20 0.43
KDM4E B2RXH2 2/20 0.43
RAB9A P51151 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTPN1 P18031 3/20 0.41
LMNA P02545 2/20 0.40
HPGD P15428 1/20 0.40
MAPKAPK2 P49137 4/20 0.40
POLB P06746 1/20 0.40
PTPN11 Q06124 1/20 0.40
NPC1 O15118 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6487288 0.88 NQO2 (0.50) MEN1KMT2AMAPTALDH1A1NPSR1
SCHEMBL6501627 0.87 MMP13 (0.43) MEN1KMT2AMMP13MAPTALDH1A1
SCHEMBL6490768 0.87 MAPKAPK2 (0.41) MEN1KMT2AMAPTTP53RXFP1
SCHEMBL6500809 0.86 NPC1 (0.43) MEN1KMT2AMAPTALDH1A1NPSR1
SCHEMBL6500577 0.85 MAPKAPK2 (0.45) MEN1KMT2AMMP13MAPTALDH1A1
SCHEMBL6500583 0.85 NPC1 (0.42) MEN1KMT2AMAPTALDH1A1NPSR1
SCHEMBL6497293 0.85 NPC1 (0.56) MMP13MAPTTP53RXFP1ALDH1A1
SCHEMBL6489260 0.85 ALDH1A1 (0.49) MEN1KMT2AMAPTALDH1A1NPSR1
SCHEMBL6488167 0.85 S1PR4 (0.43) MEN1KMT2AMAPTALDH1A1NPSR1
SCHEMBL6496600 0.83 KMT2A (0.43) MEN1KMT2AMAPTTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 MEN1 1004/4885KMT2A 3836/4885MMP13 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.